Akiba T, Shibuta T, Amano Y, Asanuma A, Okubo M, Nishigaki K, Moriwaki T, Yamada H, Okamura N, Watanabe T, Koga T, Tanaka M, Takimoto M
Fuji Research Laboratories Pharmaceutical Division, Kowa Company Ltd., Shizuoka, Japan.
J Toxicol Sci. 1998 Nov;23 Suppl 5:713-20. doi: 10.2131/jts.23.supplementv_713.
NK-104 is a novel potent inhibitor of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and has been shown to be a highly effective agent in lowering blood cholesterol. In the present study, NK-104 was orally administered to Wistar rats at a dose of 0.3, 1, 3 or 010 mg/kg for 6 months for examination of toxicity. Additional recovery groups of 8 rats each of both sexes receiving 0 and 10 mg/kg were maintained without treatment for 1 month in order to assess recovery. As a result, no toxicological changes were observed in general signs, body weight, food intake, ophthalmological examination, urinalysis, hematological and blood chemical examinations for organ weights. An autopsy revealed thickening of the forestomach mucosa in both sexes at a dose of 1 mg/kg or more. This change was microscopically recognized as hyperkeratosis and hypertrophy of the spinous layer associated with both cell infiltration of the mucosal propria and edema of sub-mucosa in the forestomach in both sexes at doses of 3 and 10 mg/kg. Forestomach changes were not observed in any cases after 1 month cessation of drug treatment. The non-toxic dose of NK-104 in the 6-month repeated oral toxicity study in rats is estimated to be 1 mg/kg/day.
NK - 104是胆固醇生物合成限速酶3 - 羟基 - 3 - 甲基戊二酰辅酶A(HMG - CoA)还原酶的新型强效抑制剂,已被证明是降低血液胆固醇的高效药物。在本研究中,以0.3、1、3或10mg/kg的剂量对Wistar大鼠口服NK - 104,持续6个月以检测毒性。另外设立恢复组,每组8只雌雄大鼠,分别给予0和10mg/kg剂量,不进行治疗,持续1个月以评估恢复情况。结果显示,在一般体征、体重、食物摄入量、眼科检查、尿液分析、血液学和血液化学检查以及器官重量方面均未观察到毒理学变化。尸检发现,剂量为1mg/kg及以上时,雌雄大鼠的前胃黏膜均增厚。在3mg/kg和10mg/kg剂量下,显微镜检查发现,雌雄大鼠前胃棘层出现角化过度和肥大,伴有黏膜固有层细胞浸润和黏膜下层水肿。停药1个月后,所有病例均未观察到前胃变化。在大鼠6个月重复口服毒性研究中,NK - 104的无毒剂量估计为1mg/kg/天。